Tools chosen: kalshi_direct claude_news claude_news kalshi_related polymarket_related congress_bills

Sub-questions (Fermi decomposition)

Planner reasoning

This is a Kalshi market about whether Trump will make IVF free (eliminating cost of at least one cycle) before Jan 20, 2029. I need the current market price, news about Trump's IVF executive actions/policies, and related markets for triangulation.

# Event Will Trump make IVF free (eliminate cost of at least one cycle) before January 20, 2029? # Outcomes to forecast - **Yes** — Trump takes action eliminating cost of ≥1 IVF cycle before Jan 20, 2029 - **No** — No such action taken # Kalshi market anchor **Current YES price: 17%** | 7-day change: +2% | 30-day change: 0% | Avg daily volume: 70 contracts | Range (63 days): 10%–18% Market has been range-bound and low-volume; the slight recent uptick is modest. # Sub-question answers 1. **Kalshi price for KXFREEIVF-29?** — 17% YES, stable over 30 days, slight +2% tick in last 7 days. [Kalshi direct] 2. **Has Trump taken action on IVF affordability?** — Yes, incrementally: Feb 2025 EO directed policy recommendations; Oct 2025 announced 84% drug discount on select fertility meds via TrumpRx.gov (launched Feb 2026) and optional employer benefit pathway ($2,150 cap). No mandate. [CNN, WhiteHouse.gov, 19th News] 3. **Specific IVF policy proposals?** — Feb 18, 2025 EO directed Domestic Policy Council to produce recommendations in 90 days (deadline missed May 2025). Oct 2025 follow-up: drug discount deal with EMD Serono (saves ~$2,200/cycle on drugs = ~20% of total cost); HHS proposed rule allowing employers to offer standalone fertility benefits voluntarily. [AJMC, PBS, WhiteHouse.gov] 4. **Pending legislation or HHS rulemaking to eliminate cost?** — No. Health Coverage for IVF Act of 2025 (Rep. Underwood) introduced May 2025, no movement. Congressional IVF mandate bills failed in 2024. White House privately retreating from insurance mandate route. Congress API search returned no relevant IVF bills. [CNN, Warren.senate.gov, congress.gov] 5. **Related prediction markets?** — No Polymarket IVF markets found. No other Kalshi IVF markets found. [Polymarket scan, Kalshi related] # Key facts (high-confidence, factual) 1. [WhiteHouse.gov] Feb 18, 2025 EO: directed Domestic Policy Council to recommend IVF cost reduction policies — no binding mandate. 2. [CNN/19th News] 90-day EO deadline (May 20, 2025) passed with no new policy announced. 3. [WhiteHouse.gov, ASRM] Oct 16, 2025: EMD Serono drug discount (84% off list) saves ~$2,200/cycle on fertility drugs; drugs = ~20% of total IVF cost. 4. [PBS/KFF] Employer fertility benefit rule: optional, capped at $2,150 — not elimination of cost. 5. [TrumpRx.gov/Prelude Fertility] TrumpRx.gov launched Feb 5, 2026 with discounted fertility drug pricing. 6. [Reproductive Freedom for All/Warren.senate.gov] White House backing away from ACA essential health benefit mandate route; no insurance mandate issued as of June 2026. 7. [Multistate.us] 25 states have fertility coverage mandates; federal mandate remains absent as of June 2026. 8. [ASRM] Full IVF cycle costs ~$12,000–$15,000+; drug discounts cover ~$2,200 of that. # Cross-market signals - **Kalshi related:** No other directly relevant IVF markets. "Trump bring back manufacturing" at 18% (similar ambitious promise, similar market skepticism). - **Polymarket:** No active IVF markets found. - **Sportsbook:** N/A # Analyst opinions and speculation - **ASRM:** Evaluates Trump initiative as meaningful but insufficient — drugs are ~20% of costs, employer pathway is voluntary. [ASRM] - **Sen. Warren:** "Trump lied when he told Americans he'd make IVF free." [Warren.senate.gov] - **KFF:** Skeptical that voluntary employer benefit pathways will materially expand access. [KFF] - **Advocacy groups:** Argue federal mandate is required; current actions don't achieve the promise. [Reproductive Freedom for All] - **Prelude Fertility (May 2026 update):** Situation largely unchanged; no new federal action imminent. # Directional lean per outcome - **Yes (IVF becomes free):** Would require either (a) Congress passing mandate legislation — stalled, Republicans opposed; (b) executive mandate on ACA plans — WH retreating; (c) Medicare/Medicaid coverage expansion — no signs. ~2.5 years remain but momentum is against this. - **No:** Strong evidence: WH retreating from mandate, voluntary-only steps taken, Congress deadlocked, missed deadlines, 80%+ of costs remain uncovered as of June 2026. # Gaps / unknowns - Whether Trump pursues an ACA "essential health benefit" rulemaking in 2027–2028 as political maneuver - Whether a budget reconciliation bill could include IVF coverage provision - How "eliminates cost of at least one IVF cycle" would be interpreted (does TrumpRx drug discount count? Almost certainly not — it only covers ~20%) - No Polymarket signal to triangulate against # Calibration anchors - **Kalshi current YES price: 17%** (primary anchor) - Pattern: Campaign promise → incremental voluntary steps → WH retreat from mandate = classic "falls short" trajectory - Analogous Kalshi: "Trump bring back manufacturing" at 18% (ambitious structural promise, similar skepticism) - ~2.5 years remain; but path to full cost elimination requires either congressional action (blocked) or executive mandate (retreating) - **Assessment:** 17% appears modestly generous given current trajectory; true probability likely 10–15% absent new political catalyst

1. Both forecasters appropriately discount from the 17% Kalshi anchor, but neither explicitly weighs the ~2.5 years remaining against a potential 2027–2028 ACA "essential health benefit" rulemaking as a last-ditch political maneuver — the brief flags this as an open unknown, and Trump has historical precedent for surprise executive moves in election-adjacent years even when momentum has stalled. 2. Neither forecaster addresses the reconciliation bill pathway mentioned in the gaps section; budget reconciliation was the vehicle used for multiple major Trump-era policy changes, and an IVF provision attached to a larger bill represents a non-trivial tail path that both essentially ignore by anchoring entirely on the direct legislative/mandate route. 3. Both forecasters treat the "White House retreating from ACA mandate" signal as roughly equivalent weight to the remaining time horizon, but the brief specifies this is based on sources through June 2026 — over 2.5 years from close, meaning the retreat is early-term positioning, not a locked trajectory, and both may be overcorrecting on a signal that could reverse. 4. The analogous "Trump bring back manufacturing" Kalshi market at 18% is cited as supporting a lower probability, but the brief itself presents this as a rough analogy rather than a tight structural parallel — manufacturing involves no clear executive action path, whereas IVF has a specific, identified mechanism (ACA EHB rulemaking) that manufacturing lacks, making the analogy weaker than both forecasters seem to assume. 5. Neither forecaster explicitly considers how the resolution criterion ("eliminates cost of at least one cycle") interacts with a potential government-negotiated zero-cost pilot program or Medicaid expansion for a specific population — partial government-funded programs that could technically satisfy the criterion but fall short of universal free IVF, which is a scenario the brief does not fully close off.

12% (50% confidence)

Yes: 12% No: 88%

Anchoring near the Kalshi 17% but discounting modestly given concrete evidence of WH retreat from mandate, missed deadlines, and that current actions cover only ~20% of cycle cost. Retain some mass for tail paths (ACA EHB rulemaking, reconciliation, or narrow pilot satisfying the criterion) given ~2.5 years remain. Settling at 12% balances forecaster consensus with the critique's reminder not to over-discount the time horizon.

Total pipeline time: 109.1s